Literature DB >> 28475868

Glucocorticoid Receptor:MegaTrans Switching Mediates the Repression of an ERα-Regulated Transcriptional Program.

Feng Yang1, Qi Ma1, Zhijie Liu2, Wenbo Li3, Yuliang Tan1, Chunyu Jin1, Wubin Ma1, Yiren Hu4, Jia Shen1, Kenneth A Ohgi1, Francesca Telese1, Wen Liu5, Michael G Rosenfeld6.   

Abstract

The molecular mechanisms underlying the opposing functions of glucocorticoid receptors (GRs) and estrogen receptor α (ERα) in breast cancer development remain poorly understood. Here we report that, in breast cancer cells, liganded GR represses a large ERα-activated transcriptional program by binding, in trans, to ERα-occupied enhancers. This abolishes effective activation of these enhancers and their cognate target genes, and it leads to the inhibition of ERα-dependent binding of components of the MegaTrans complex. Consistent with the effects of SUMOylation on other classes of nuclear receptors, dexamethasone (Dex)-induced trans-repression of the estrogen E2 program appears to depend on GR SUMOylation, which leads to stable trans-recruitment of the GR-N-CoR/SMRT-HDAC3 corepressor complex on these enhancers. Together, these results uncover a mechanism by which competitive recruitment of DNA-binding nuclear receptors/transcription factors in trans to hot spot enhancers serves as an effective biological strategy for trans-repression, with clear implications for breast cancer and other diseases.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  enhancers; nuclear receptors; transcriptional regulation; transrepression

Mesh:

Substances:

Year:  2017        PMID: 28475868      PMCID: PMC5510478          DOI: 10.1016/j.molcel.2017.03.019

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  70 in total

1.  Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity.

Authors:  F Ann Ran; Patrick D Hsu; Chie-Yu Lin; Jonathan S Gootenberg; Silvana Konermann; Alexandro E Trevino; David A Scott; Azusa Inoue; Shogo Matoba; Yi Zhang; Feng Zhang
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

2.  Genome-wide analysis of estrogen receptor binding sites.

Authors:  Jason S Carroll; Clifford A Meyer; Jun Song; Wei Li; Timothy R Geistlinger; Jérôme Eeckhoute; Alexander S Brodsky; Erika Krasnickas Keeton; Kirsten C Fertuck; Giles F Hall; Qianben Wang; Stefan Bekiranov; Victor Sementchenko; Edward A Fox; Pamela A Silver; Thomas R Gingeras; X Shirley Liu; Myles Brown
Journal:  Nat Genet       Date:  2006-10-01       Impact factor: 38.330

3.  Sequential chromatin immunoprecipitation protocol: ChIP-reChIP.

Authors:  Mayra Furlan-Magaril; Héctor Rincón-Arano; Félix Recillas-Targa
Journal:  Methods Mol Biol       Date:  2009

4.  Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer.

Authors:  Deng Pan; Masha Kocherginsky; Suzanne D Conzen
Journal:  Cancer Res       Date:  2011-08-25       Impact factor: 12.701

5.  Nonparametric estimation of lifetime and disease onset distributions from incomplete observations.

Authors:  G E Dinse; S W Lagakos
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

6.  Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells.

Authors:  Duohui Jing; Vivek A Bhadri; Dominik Beck; Julie A I Thoms; Nurul A Yakob; Jason W H Wong; Kathy Knezevic; John E Pimanda; Richard B Lock
Journal:  Blood       Date:  2014-10-21       Impact factor: 22.113

7.  Role of transcriptional coregulator GRIP1 in the anti-inflammatory actions of glucocorticoids.

Authors:  Yurii Chinenov; Rebecca Gupte; Jana Dobrovolna; Jamie R Flammer; Bill Liu; Francesco E Michelassi; Inez Rogatsky
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

8.  Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling.

Authors:  Nicholas T Ingolia; Sina Ghaemmaghami; John R S Newman; Jonathan S Weissman
Journal:  Science       Date:  2009-02-12       Impact factor: 47.728

9.  GOBO: gene expression-based outcome for breast cancer online.

Authors:  Markus Ringnér; Erik Fredlund; Jari Häkkinen; Åke Borg; Johan Staaf
Journal:  PLoS One       Date:  2011-03-21       Impact factor: 3.240

10.  Design and analysis of ChIP-seq experiments for DNA-binding proteins.

Authors:  Peter V Kharchenko; Michael Y Tolstorukov; Peter J Park
Journal:  Nat Biotechnol       Date:  2008-11-16       Impact factor: 54.908

View more
  25 in total

Review 1.  Nuclear receptor crosstalk - defining the mechanisms for therapeutic innovation.

Authors:  Karolien De Bosscher; Sofie J Desmet; Dorien Clarisse; Eva Estébanez-Perpiña; Luc Brunsveld
Journal:  Nat Rev Endocrinol       Date:  2020-04-17       Impact factor: 43.330

2.  Lessons from eRNAs: understanding transcriptional regulation through the lens of nascent RNAs.

Authors:  Joseph F Cardiello; Gilson J Sanchez; Mary A Allen; Robin D Dowell
Journal:  Transcription       Date:  2019-12-19

3.  Nonlinear relationship between chromatin accessibility and estradiol-regulated gene expression.

Authors:  Duojiao Chen; Taylor M Parker; Poornima Bhat-Nakshatri; Xiaona Chu; Yunlong Liu; Yue Wang; Harikrishna Nakshatri
Journal:  Oncogene       Date:  2021-01-08       Impact factor: 9.867

4.  Clinical and Genomic Crosstalk between Glucocorticoid Receptor and Estrogen Receptor α In Endometrial Cancer.

Authors:  Jeffery M Vahrenkamp; Chieh-Hsiang Yang; Adriana C Rodriguez; Aliyah Almomen; Kristofer C Berrett; Alexis N Trujillo; Katrin P Guillen; Bryan E Welm; Elke A Jarboe; Margit M Janat-Amsbury; Jason Gertz
Journal:  Cell Rep       Date:  2018-03-13       Impact factor: 9.423

5.  Psychosocial Stress Exposure Disrupts Mammary Gland Development.

Authors:  Marianna B Johnson; Joscelyn N Hoffmann; Hannah M You; Ricardo R Lastra; Sully Fernandez; Jordan W Strober; Ahmad B Allaw; Matthew J Brady; Suzanne D Conzen; Martha K McClintock
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-04-23       Impact factor: 2.673

6.  Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor.

Authors:  Maud Voisin; Philippe de Medina; Arnaud Mallinger; Florence Dalenc; Emilie Huc-Claustre; Julie Leignadier; Nizar Serhan; Régis Soules; Grégory Ségala; Aurélie Mougel; Emmanuel Noguer; Loubna Mhamdi; Elodie Bacquié; Luigi Iuliano; Chiara Zerbinati; Magali Lacroix-Triki; Léonor Chaltiel; Thomas Filleron; Vincent Cavaillès; Talal Al Saati; Philippe Rochaix; Raphaelle Duprez-Paumier; Camille Franchet; Laetitia Ligat; Fréderic Lopez; Michel Record; Marc Poirot; Sandrine Silvente-Poirot
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-12       Impact factor: 11.205

Review 7.  Chromatin reprogramming in breast cancer.

Authors:  Erin E Swinstead; Ville Paakinaho; Gordon L Hager
Journal:  Endocr Relat Cancer       Date:  2018-04-24       Impact factor: 5.678

8.  Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.

Authors:  Diana C West; Masha Kocherginsky; Eva Y Tonsing-Carter; D Nesli Dolcen; David J Hosfield; Ricardo R Lastra; Jason P Sinnwell; Kevin J Thompson; Kathleen R Bowie; Ryan V Harkless; Maxwell N Skor; Charles F Pierce; Sarah C Styke; Caroline R Kim; Larischa de Wet; Geoffrey L Greene; Judy C Boughey; Matthew P Goetz; Krishna R Kalari; Liewei Wang; Gini F Fleming; Balázs Györffy; Suzanne D Conzen
Journal:  Clin Cancer Res       Date:  2018-04-10       Impact factor: 12.531

Review 9.  Deciphering Steroid Receptor Crosstalk in Hormone-Driven Cancers.

Authors:  Thu H Truong; Carol A Lange
Journal:  Endocrinology       Date:  2018-12-01       Impact factor: 4.736

Review 10.  The Role of Psychologic Stress in Cancer Initiation: Clinical Relevance and Potential Molecular Mechanisms.

Authors:  Marta Falcinelli; Premal H Thaker; Susan K Lutgendorf; Suzanne D Conzen; Renée L Flaherty; Melanie S Flint
Journal:  Cancer Res       Date:  2021-07-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.